ArticleOrphanet journal of rare diseases2025
The impact of the COVID-19 pandemic on incidence and clinical presentation of thrombotic microangiopathies: data from a laboratory centralizing ADAMTS-13 testing in Quebec.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Capillary stalling: A common microvascular pathway to stroke susceptibility and poor recovery.Neurobiology of disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCoronavirus disease 2019 (COVID-19) primarily induces respiratory symptoms. However, some patients develop thrombotic microangiopathies (TMA) during their infection. This study aimed to compare the incidence and clinical presentation of patients referred for TMA suspicion in Quebec (Canada) before and during the COVID-19 pandemic, utilizing data from a laboratory centralizing ADAMTS-13 testing.
resultsDuring the pre-pandemic period (2017–2019), 500 patients were referred for TMA suspicion, of whom 423 had no prior TMA episodes. Among these, 50 patients exhibited ADAMTS-13 activity ≤ 10%, confirming a diagnosis of thrombotic thrombocytopenic purpura (TTP). In the pandemic period (2020–2022), 683 patients were referred for TMA suspicion, with 600 experiencing their first TMA episode. TTP was identified in 53 patients. In our cohort, the mean incidence of TTP cases remained steady between the pre-pandemic and the pandemic period (approximately 2 cases per million persons per year). Females with TTP were younger during the pandemic compared to the pre-pandemic period (median age 41.5 vs. 51.5 years; p = 0.032). Overall, the clinical presentation of TTP and suspected TMA other than TTP patients remained comparable between the two periods. The mean incidence of suspected TMA other than TTP cases increased in males during the pandemic compared to the previous period (20.3 vs. 12.7 per million persons per year; p = 0.023), particularly in men aged 50–59 years (28.7 vs. 11.9 per million persons per year; p = 0.05). A weak cross-correlation between new COVID-19-related hospitalizations and new cases of suspected TMA other than TTP was observed, peaking at a lag of 1 week (r = 0.258). COVID-19-associated TMA was suspected in 17 patients, with 3 cases confirmed as TTP based on ADAMTS-13 activity results. Patients with suspected TMA other than TTP associated with COVID-19 were predominantly male (86%) with a median age of 53 years (IQR: 43.2–69.2).
conclusionThe incidence of TTP did not change during COVID-19 pandemic. An increase referral of other suspected TMA was observed in our cohort, especially in males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.